Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.48 |
| ▸ | CDK8 | P49336 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.38 |
| ▸ | CHUK | O15111 | 2/20 | 0.38 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19769153 | 0.86 | CDK8 (0.56) | IKBKBCDK8CDK19 | |
| SCHEMBL19769165 | 0.85 | CDK8 (0.58) | IKBKBCDK8CDK19 | |
| SCHEMBL19769156 | 0.83 | IKBKB (0.47) | IKBKBCDK8CDK19 | |
| SCHEMBL19769168 | 0.83 | IKBKB (0.51) | IKBKBCDK8CYP3A4CDK19 | |
| SCHEMBL19769189 | 0.81 | CDK8 (0.43) | IKBKBCDK8CDK19 | |
| SCHEMBL19769124 | 0.81 | CDK8 (0.43) | IKBKBCDK8CDK19 | |
| SCHEMBL19769126 | 0.81 | CDK8 (0.43) | IKBKBCDK8CDK19 | |
| SCHEMBL19769119 | 0.81 | CDK8 (0.44) | IKBKBCDK8CDK19 | |
| SCHEMBL19769170 | 0.79 | CDK8 (0.46) | IKBKBCDK8CDK19 | |
| SCHEMBL19769121 | 0.78 | CDK8 (0.41) | IKBKBCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10154992-B2 | Compounds and methods for treating HIV infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10154992-B2 | Compounds and methods for treating HIV infection | CD4, CCR5, MMP8 | IKBKB 1036/4885CDK8 1366/4885CYP3A4 309/4885 |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | CD4, CCR5, MMP8 | IKBKB 1036/4885CDK8 1366/4885CYP3A4 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.